Kornimate/medical-research-clean huggingface dataset:
the effect of calcium β-hydroxy-β-methylbutyrate (cahmb) supplementation in sarcopenia in liver cirrhosis

Conditions: Sarcopenia; Cirrhosis, Liver

Summary: this study is to evaluate the effect of cahmb in the treatment of sarcopenia in liver cirrhosis.

the study is a randomized double-blind controlled trial. patients randomly enter into two treatment groups: 1) the cahmb group and 2) the placebo group. treatment allocation is by block randomization, with an one-to-one ratio for cahmb and placebo. the results are concealed in opaque envelopes. patients will report their daily diets with an online software. patients will come for clinic after 4 weeks and 12 weeks, receiving laboratory tests and sarcopenia evaluation, and events of primary and secondary outcomes will be analyzed.

Eligibility criteria:
inclusion criteria: 1. diagnosed of cirrhosis with imaging or liver biopsy; 2. diagnosis of portal hypertension with endoscopy or radiography； 3. assessed total muscle mass at the level of l3 (\<42 cm2/m2 for male and \<38 cm2/m2 for female) 4. has signed an informed consent form. exclusion criteria: 1. diagnosed as hepatic cell cancer; 2. complicated with malignancy, renal failure, diabetes mellitus; 3. comorbidities including heart failure or pulmonary disease; 4. current use of drugs that affect skeletal muscle metabolism; 5. be allergic to the experimental food; 6. participated other clinical trials in the past 3 months; 7. other conditions that researchers consider not suitable for this study

Keywords: hmb sarcopenia liver cirrhosis chronic liver disease malnutrition muscle wasting
treatment of medial humeral epicondyle fractures in children with absorbable cartilage nails

Conditions: Fracture Arm

Summary: to compare surgical outcomes from medial epicondyle fracture fixation with absorbable cartilage nails to those from traditional kirschner wire fixation.

from august 2007 to january 2012, 32 patients undergoing surgery for medial humeral epicondyle fractures in our hospital were randomized into group a (traditional kirschner wire) or group b (absorbable cartilage nail). the same surgical team performed the operations, and patients were followed for over a year. group a had open reduction with k-wire fixation, and group b was fixed with absorbable cartilage nails. the bede scoring system was used to evaluate elbow function at follow-up.

Eligibility criteria:
inclusion criteria: * fractures with more than 2 mm of displacement were treated with cast immobilization exclusion criteria: * fractures with less than 2 mm of displacement were treated with cast immobilization

Keywords: medial epicondyle humerus absorbable cartilage nail
a research study comparing how well different doses of the medicine nn0519-0130 lower blood sugar in people with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: this study will look at how well a new medicine called nnc0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. the study will test up to 7 different doses of nnc0519-0130. which treatment participant will get is decided by chance. participants will take 1-3 injections once a week. the study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. the study will last for about 40 weeks.


Eligibility criteria:
inclusion criteria: * female of non-childbearing potential, or male. * for united states (us) only: female of childbearing potential using highly effective non-systemic methods of contraception with low user-dependency and willingness to continue using it through-out the study or male. * age 18-75 years (both inclusive) at the time of signing the informed consent. * diagnosed with type 2 diabetes mellitus greater than or equal 180 days before screening. * stable daily dose(s) more than or equal 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without sodium-glucose co-transporter 2 (sglt2) inhibitor. * glycated haemoglobin (hba1c) of 7.5-10.0% (58-86 millimoles per moles (mmol/mol)) (both inclusive) as assessed by central laboratory at screening. * body mass index (bmi) greater than or equal 23.0 kilograms per meter square (kg/m\^2). exclusion criteria: * treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. however, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed. * uncontrolled and potentially unstable diabetic retinopathy or maculopathy. verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * known hypoglycaemic unawareness as indicated by the investigator according to clarke's questionnaire question.
effect of cyanoacrylate and concentrated growth factor on palatal donor site

Conditions: Wound Healing; Pain; Patient Comfort

Summary: the aim of this planned randomized controlled clinical study is to evaluate the morbidity of the palatal donor area after free gingival graft (fgg) operations. in this study, wound healing and pain levels in the palatal region will be evaluated after cyanoacrylate and concentrated growth factor (cgf) applications.

free gingival graft obtained in the palatal region causes morbidity. therefore, clinicians try to overcome these difficulties by isolating the wound in the palatal region from the oral environment and/or accelerating wound healing. periodontal dressings, acrylic stents, hemostatic agents, surgical sponges, platelet concentrates, low-level laser therapy, photobiomodulation, cyanoacrylate tissue adhesives and hyaluronic acid are some of the methods used for donor site management or to accelerate healing. cyanoacrylate adhesives form an adhesive film through rapid polymerization triggered by the hydroxyl groups on the surfaces to which they are applied. they have both bacteriostatic and hemostatic properties. in recent years, it has been observed that the use of platelet concentrates such as platelet rich plasma (prp), platelet rich fibrin (prf) and autogenous products such as cgf (concentrated growth factor) in periodontal treatments has increased. cgf is obtained by centrifuging blood in four different cycles and times. this product contains a relatively intact fibrin clot containing platelets, leukocytes, various growth factors and cytokines. cgf can be applied as a carrier of growth factors and/or a barrier membrane to aid tissue regeneration and wound healing in clinical applications. the aim of this planned randomized controlled clinical study is to evaluate the morbidity of the palatal donor area after fgg operations. in this study, wound healing and pain levels in the palatal region will be evaluated after cyanoacrylate and cgf applications.

Eligibility criteria:
inclusion criteria: * systemically healthy * not had periodontal surgery in the last 6 months exclusion criteria: * smoker * allergic to medication * high anxiety (using modified dental anxiety scale)

Keywords: cyanoacrylate free gingival graft concentrated growth factor
efficacy and safety of the administration of ondansetron versus habitual clinical practice for the treatment of vomiting in children with mild and moderate dehydration: randomized clinical trial

Conditions: Vomiting in Infants and/or Children

Summary: this clinical trial is intended to evaluate the efficacy and safety of the administration of ondansetron in children with mild-moderate dehydration. the target population will be children between 4 and 13 years old who present vomiting.


Eligibility criteria:
inclusion criteria: * presence of at least 2 vomits in the last 4 hours. * negative tolerance test. * signature of the informed consent by the parents or legal guardians. * diagnosis of vomiting or diagnosis of acute gastroenteritis with vomiting. * patients weighing 15 kg or more. exclusion criteria: * altered conciousness. * sospected acute abdomen (appendicitis, invaginations...). * suspicion or presence of obstructive disease. * known severe digestive disease (chron´s disease, ulcerative colitis...). * suspected food poisoning. * allergy to any of the drugs used in the study. * severe dehydration. * bilious vomiting. * previous abdominal surgery. * pathology that may affective degree of hydration of the patient (kidney failure, hypoalbuminemia..). * admission requirement or intravenous rehydration for any reason. * concomitant use of apomorphine. * in relation to the possible lengthening of the qt, patients with problems of previous arrhythmia should be excluded or that they are receiving concomitant medication that can lengthen the qt, that have electrolyte disturbances. * patients receiving other serotonergic drugs. * patients who have undergone a previous adenotonsillectomy. * patients with hypocalcemia and/or hypomagnesemia. * patients with hereditary fructose intolerance. * diabetes patients. * lactose intolerant patients. * patients with indication of the low sodium diets. * hypersensitivity to ondansetron or other antagonists of the 5-ht3.
efficacy and safety of unfractionated heparin in patients with cardiovascular surgery using cardiopulmonary bypass

Conditions: Prevention of Venous Thromboembolism

Summary: the primary objective of this study is to verify, through a randomized, blinded, parallel clinical trial, the efficacy of bovine heparin from bergamo laboratory actiparin ® product when compared to porcine heparin app pharmaceutical in patients undergoing surgery cardiovascular disease and who require cardiopulmonary bypass, through the control of hemostasis during and after surgery, based on measurements of markers of coagulation act, aptt, anti-xa heparin levels and the excessive blood loss (hemorrhage) after the end of surgery.


Eligibility criteria:
inclusion criteria: * patients who agree with all aspects of the study and sign the fict; * patients of both sexes; * patients over the age of 18 years; * patients with indication for cardiac surgery requiring cardiopulmonary bypass. exclusion criteria: * patients with hematological disorders that compromise the surgical outcome (eg, myeloproliferative disorders, anemia, hb \<11.0 g / dl, platelets \<100,000 mm3); * patients with disorders of hemostasis (inr\> 1.40) (apttr\> 1.40); * patients with renal impairment (creatinine\> 1.50); * patients with deep hyperthermia; * liver disease (ast and alt\> 2 times that of the reference value); * patients with a history of allergy to heparin or protamine; * patients with a history of heparin-induced thrombocytopenia; * infection (eg endocarditis, septicemia and pneumonia); * reoperations; * use of antiplatelet agents (clopidogrel and ticlopidine) for less than 7 days; * use of aspirin for less than 5 days; * use of heparin, low molecular weight less than 24 hours; * use of unfractionated heparin for less than 12 hours.
probiotic on atopic dermatitis in infant

Conditions: Atopic Dermatitis

Summary: the clinical trial will be carried out in china medical university hospital. the overall plan is a double-blind trial. all recruited 1-3 years old atopic dermatitis (ad) patients are divided into two groups, 50 in each group and 100 in two groups. the two groups are placebo and bifidobacterium longum ccfm1029. the entire evaluation plan lasts for nine months. the number of probiotic bacteria is 50 billion per capsule, and the number of bacteria taken by the subjects is 50 billion per day (one capsule before bed each day). during the planning period, the eczema area and severity index (easi) score of the patient's dermatitis was evaluated every three month, and the score differences of dermatitis before and after taking probiotics was observed. three months before and after blood tests for ige, ecp, tslp, ifn-γ, il-4, il-5, il-13, tnf-α, ccl5(rantes), tgf-β, il-1ra, and evaluation of probiotic supplementation, whether that can reduce allergies and inflammatory indexes in the body. in addition, subjects must perform two fecal samplings before and after the trial, and the isolated dna was analyzed using the next-generation high-throughput sequencing method (ngs) for subject fecal flora changes. comparing the two groups before and after taking the capsule, whether the intestinal flora changed. statistical analysis of the relationship between changes in intestinal flora and the degree of ad. through the above test, the investigators evaluated whether bifidobacterium longum ccfm1029 can regulate the pediatric intestinal flora and relieve the inflammatory response in the body, thereby regulating atopic dermatitis.


Eligibility criteria:
inclusion criteria: * subjects were between 1 and 3 years old. * for patients diagnosed with atopic dermatitis by a professional physician and the easi score is greater than 10, the type and frequency of drugs used during the experiment should be recorded. * the subject's parents agree to join the trial and sign the informed consent form. exclusion criteria: * the patient who has a history of allergic reactions, or the use of other highly sensitive or contraindicated drugs (allergy to antibiotics or antipyretics). * the patient who has taken oral immunosuppressants and systemic steroids within the past 2 weeks. * the patient who has consumed probiotic-related products (including drops, lozenges, capsules, powder or yogurt) within the past 1 month. * the patient who has participated in other clinical studies within the past 1 month. * the patient who has received immunotherapy within the past 1 year. * the patient who suffering from major diseases (with a ic card for severe illness), congenital diseases. * the patient who is not suitable to participate in the trial as assessed by the professional physician.

Keywords: atopic dermatitis probiotics intestinal flora allergic diseases
real world and epidemiology study of medically attended chlamydia trachomatis among adults in germany

Conditions: Chlamydia Trachomatis

Summary: this study assesses the epidemiologic situation of chlamydia trachomatis, its complications and long term sequalae and related healthcare resource utilization and costs among adults in germany. the study is a retrospective cohort study based on german statutory health insurance (shi) claims data for adolescents and adults aged 14 to 44 years in the years 2008-2022 with documented (confirmed) diagnosis of ct. study objectives are to: 1. estimate frequency of potential short-term complications and long-term sequelae in patients with medically attended chlamydia infection 2. analyze time from first documented prevalent ct infection to first potential complication/sequelae diagnosis 3. estimate frequency of re-infection (chlamydia recurrence) and co-infections with other sexually transmitted infections (stis) in patients with medically-attended chlamydia infection 4. estimate absolute healthcare resource utilization (by level of care and specialty) and costs in patients with chlamydia infection, including for potential short-term complications and long-term sequelae 5. estimate administrative prevalence of medically-attended chlamydia infection in the overall study population 6. estimate administrative prevalence of diagnoses potentially associated with a chlamydia infection (i.e., short-term complications/long-term sequelae) in the overall study population 7. estimate frequency of chlamydia testing in the overall study population


Eligibility criteria:
inclusion criteria: * either male or female is documented as gender in base data * at cohort entry, a patient must be aged between 14 and 44 years exclusion criteria: * none
acute and long-term impact of cancer treatment on head and neck cancer patients: fit4treatment

Conditions: Head and Neck Neoplasms

Summary: head and neck squamous cell carcinoma (hnscc) is the 6th most common cancer. most cases are diagnosed in locally advanced stages, with treatment involving multimodal approach with combinations of radiotherapy, surgery and chemotherapy. the aggressive nature of hnsccs and treatment modalities are associated with important acute and late toxicities that often promote temporary or definitive treatment interruption and may compromised the capability to tolerate subsequent treatments. thus, the aim of this study is to analyze the acute and long-term impact of cancer treatment on quality of life, physical and cognitive function of hnscc patients diagnosed with a locally advanced disease.

potential cases will be identified at the multidisciplinary head and neck group meeting. if the case meets eligibility an informed consent will be presented to the patient. interested participants will be scheduled for baseline assessment before the beginning of treatment (m0). at the end of crt patients will be submitted to a second assessment (m1). follow-up assessments will occur 16th to 18th weeks after the treatment is completed (m2). patients proposed to surgery or induction chemotherapy will also be submitted to an additional assessment before the beginning of crt (mc / mic).

Eligibility criteria:
inclusion criteria: * patients older than 18 years. * diagnosis of locally advanced head and neck cancer (oral cavity, oropharynx, hypopharynx, larynx), stage iii-ivb. * proposed for primary treatment with curative intent - surgery or induction chemotherapy before chemoradiotherapy (crt) or crt alone. exclusion criteria: * synchronous tumors or other comorbidities with associated uncontrolled symptoms. * inability to provide informed consent. * expected inability to fulfil the propose schedule and follow-up.

Keywords: head and neck neoplasms acute adverse events long-term adverse events quality of life cognitive function physical function
study of kerastat cream for radiation dermatitis during head and neck radiotherapy

Conditions: Head and Neck Cancer; Radiation Dermatitis

Summary: this is a single site, randomized, open-label comparison pilot study to assess the feasibility and effectiveness of kerastat cream compared with routine skin care (rsc) in managing radiotherapy-induced early adverse skin reaction (easr) in patients undergoing radiotherapy to the head and/or neck. hypothesis: the use of kerastat cream in patients receiving radiotherapy for head and neck is feasible, tolerable, and reduces the severity of early adverse skin reaction in the treated region of interest.

primary objective(s) • to determine the feasibility of the use of kerastat cream in patients receiving radiotherapy for head and neck cancer. secondary objective(s) * to determine the tolerability of kerastat cream in patients receiving radiotherapy for head and neck cancer compared to routine skin care. * to assess the effectiveness of kerastat cream in reducing the severity of easr in patients receiving radiotherapy for head and neck cancer, compared to routine skin care. this will be performed by evaluating: * objective evaluation of easr using the ctcae version 5.0 scale of radiation dermatitis, * patient-reported outcomes of radiation dermatitis using the pro-ctcae version 1.0, and * dermatologic-specific quality of life assessment * to estimate the amount of kerastat cream used per patient and coverage on the skin.

Eligibility criteria:
inclusion criteria: * diagnosis of head and neck cancer planned to receive conventionally-fractionated definitive radiotherapy to the head and neck to a total prescribed dose of at least 60 gy * able and willing to sign protocol consent form * able and willing to complete tolerability and quality of life assessments * able and willing to have photographs of the affected area taken regularly exclusion criteria: * women who are pregnant, lactating/nursing or plan to become pregnant * previous radiation therapy to the area to be treated with radiation therapy * active, medically necessary use of topical corticosteroids in the irradiation area * active scleroderma or lupus requiring systemic medication * treatment with anti-egfr antibodies for head and neck cancer (previously or planned)
aztreonam for inhalation (ai) in patients with cystic fibrosis & p. aeruginosa infection

Conditions: Cystic Fibrosis; CF; Lung Infection; Pseudomonas Aeruginosa

Summary: this is multicenter placebo-controlled study evaluating the safety and efficacy of ai at two dosage levels compared to placebo in cf patients with p. aeruginosa lung infection.

this is multicenter placebo-controlled study evaluating the safety and efficacy of a 14-day treatment of ai at two dosage levels as compared to placebo, given twice daily, in cf patients with p. aeruginosa lung infection, delivered by the eflow investigational nebulizer.

Eligibility criteria:
inclusion criteria: * written informed consent prior to the performance of any study related procedures. * 13 years of age and above. * documented sweat chloride ≥ 60 meq/l by quantitative pilocarpine iontophoresis test (qpit) or homozygosity for δf508 genetic mutation or heterozygosity for two well characterized mutations. * ability to perform pulmonary function tests. * fev1 ≥ 40% predicted at visit 1 (screening). * sao2 ≥ 90% at visit 1 (screening). * p. aeruginosa present in sputum at visit 1 (screening). * ability to expectorate sputum on a daily basis. exclusion criteria: * administration of any antibiotic with antipseudomonal activity by any route within 56 days prior to visit 1 (screening). * administration of any investigational drug or device within 28 days of visit 1 (screening) and within 6 half-lives of the investigational drug. * oral corticosteroids in doses exceeding 10 mg per day or 20 mg every other day. * history of sputum culture or throat swab culture yielding b. cepacia in the previous two years. * current daily continuous oxygen supplementation or requirement for more than 2 l/min at night. * known local or systemic hypersensitivity to monobactam antibiotics. * changes in antimicrobial, bronchodilator, anti-inflammatory or corticosteroid medications within 7 days prior to visit 1 (screening). * changes in physiotherapy technique or schedule within 7 days prior to visit 1 (screening). * history of lung transplantation. * a chest radiograph at visit 1 (screening) or within the previous 90 days of screening, with abnormalities indicating a significant acute finding (eg, lobar infiltrate and atelectasis, pneumothorax, or pleural effusion). * abnormal renal or hepatic function or serum chemistry at visit 1 (screening): * ast, alt \> 2.5 times upper limit of normal range. * creatinine \> 1.5 times upper limit of normal range. * positive pregnancy test. all women of childbearing potential will be tested. * female of childbearing potential who is lactating or is not practicing acceptable method of birth control (eg, hormonal or barrier methods, or iud). * findings at visit 1 (screening) that, in the investigator's opinion, would compromise the safety of the patient or the quality of the study data.

Keywords: cystic fibrosis cf aztreonam lung infection pseudomonas aeruginosa